Melatonin and melatonin receptor agonists in the treatment of nocturia: A systematic review.
benign prostatic hyperplasia
insomnia
lower urinary tract symptoms
overactive bladder
sleep disorder
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
revised:
19
02
2024
received:
08
12
2023
accepted:
28
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
aheadofprint
Résumé
Causes of nocturia may extend beyond primary bladder pathology and it has been commonly associated as a side effect of sleep disorders. This has led to the study of melatonin and melatonin receptor agonists as a primary treatment for nocturia hypothesized to be secondary to sleep disorders. We aim to systematically review the efficacy and reported safety of melatonin and melatonin receptor agonists in the treatment of nocturia. A search strategy of EMBASE and Pubmed/Medline databases was utilized to identify eligible studies. Two thousand and twenty-eight unique references were identified in concordance with the Preferred Reporting Items of Systematic Reviews and Meta-Analyses guidelines for systematic reviews, of which nine papers met the inclusion criteria. The Cochrane Collaboration risk of bias criteria in the open label and nonplacebo studies was used to assess bias. The nine studies identified included 3 randomized double-blinded placebo-controlled trials, 2 randomized non-placebo trial, and 4 prospective open-label trials. Three utilized the melatonin-receptor agonist ramelteon (8 mg) and six utilized melatonin (four 2 mg extended release, two 2 mg normal release). Nocturia improved in 8 studies varying from moderate to low efficacy related to reduction in nocturia episodes. Five studies evaluated sleep parameters finding improvement in both nocturia and sleep quality. Male subjects represented 76.8% of 371 total subjects in prospective and randomized trials. Ramelteon and melatonin were both reported as well tolerated during nocturia treatment. A meta-analysis was not able to be performed due to the heterogeneity of bladder diagnoses. At this time, there is insufficient evidence to routinely recommend melatonin as an effective treatment for nocturia given the limitations of current clinical studies. Randomized placebo-controlled trials and prospective open label studies in non-neurogenic populations report a trend towards nocturia improvement with good tolerability and rare side effects. Therefore, further larger scale randomized trials with focused urologic diagnoses in well-characterized patient populations are warranted.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Neurourology and Urodynamics published by Wiley Periodicals LLC.
Références
Tikkinen KAO, Auvinen A, Johnson TM, et al. A systematic evaluation of factors associated with nocturia-the population-based FINNO study. Am J Epidemiol. 2009;170(3):361-368. doi:10.1093/aje/kwp133
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1315. doi:10.1016/j.eururo.2006.09.019
Bliwise DL, Wagg A, Sand PK. Nocturia: a highly prevalent disorder with multifaceted consequences. Urology. 2019;133:3-13. doi:10.1016/j.urology.2019.07.005
Weiss JP, Lee KC. Nocturia: Etiology, Pathology, Risk Factors, Treatment and Emerging Therapies. Academic Press; 2020. doi:10.1016/C2019-0-01208-3
Clemens JQ, Wiseman JB, Smith AR, et al. Prevalence, subtypes, and correlates of nocturia in the symptoms of lower urinary tract dysfunction research network cohort. Neurourol Urodyn. 2020;39(4):1098-1107. doi:10.1002/nau.24338
Pesonen JS, Vernooij RWM, Cartwright R, et al. The impact of nocturia on falls and fractures: a systematic review and meta-analysis. J Urol. 2020;203(4):674-683. doi:10.1097/JU.0000000000000459
Lee KC, Weiss JP. Epidemiology and prevalence. Nocturia. 2020;1:23-28. doi:10.1016/b978-0-12-820097-1.00003-2
Destors M, Tamisier R, Sapene M, et al. Nocturia is an independent predictive factor of prevalent hypertension in obstructive sleep apnea patients. Sleep Med. 2015;16(5):652-658. doi:10.1016/j.sleep.2014.10.019
Weiss JP, Blaivas JG. Nocturnal polyuria versus overactive bladder in nocturia. Urology. 2002;60(5 suppl 1):28-32. doi:10.1016/S0090-4295(02)01789-2
Dimet-Wiley A, Golovko G, Watowich SJ. One-Year postfracture mortality rate in older adults with hip fractures relative to other lower extremity fractures: retrospective cohort study. JMIR Aging. 2022;5(1):e32683. doi:10.2196/32683
Supplements: a nationally representative multi-mode survey, June/July 2022 results. 2022.
Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in use of melatonin supplements among US adults, 1999-2018. JAMA. 2022;327(5):483-485. doi:10.1001/jama.2021.23652
Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27(1):87-98. doi:10.1185/03007995.2010.537317
Fatemeh G, Sajjad M, Niloufar R, Neda S, Leila S, Khadijeh M. Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials. J Neurol. 2022;269(1):205-216. doi:10.1007/s00415-020-10381-w
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
Leerasiri P, Pariyaeksut P, Hengrasmee P, Asumpinwong C. Effectiveness of melatonin for the treatment of nocturia: a randomized controlled trial. Int Urogynecol J. 2023;34(2):485-492. doi:10.1007/s00192-022-05232-3
Drake MJ, Canham L, Cotterill N, et al. Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS. BMC Neurol. 2018;18(1):107. doi:10.1186/s12883-018-1114-4
Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol. 2004;171(3):1199-1202. doi:10.1097/01.ju.0000110442.47593.ea
Sugaya K, Nishijima S, Miyazato M, Kadekawa K, Ogawa Y. Effects of melatonin and rilmazafone on nocturia in the elderly. J Int Med Res. 2007;35(5):685-691. doi:10.1177/147323000703500513
Park MJ, Seo SY, Park HJ, Park JH, Lim MY, Park NC. Therapeutic effects of prolonged release melatonin (Circadin®) in patients with overactive bladder and chronic insomnia in more than 55 years old. Kosin Med J. 2020;35(2):101-113. doi:10.7180/kmj.2020.35.2.101
Batla A, Simeoni S, Uchiyama T, et al. Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson's disease. Eur J Neurol. 2021;28(6):1884-1892. doi:10.1111/ene.14774
Kawahara T, Morita S, Ito H, et al. Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia. BMC Urol. 2013;13:30. doi:10.1186/1471-2490-13-30
Shimizu N, Sugimoto K, Nozawa M, et al. Efficacy of ramelteon in patients with insomnia and nocturia. LUTS. 2013;5(2):69-74. doi:10.1111/j.1757-5672.2012.00166.x
Shimizu N, Nozawa M, Sugimoto K, et al. Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms. Res Rep Urol. 2013;5:113-119.
Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(7829):d5928. doi:10.1136/bmj.d5928
Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301-310. doi:10.1016/j.neuropharm.2004.09.007
Doghramji K. Melatonin and its receptors: a new class of sleep-promoting agents. J Clin Sleep Med. 2007;3(5 suppl):S17-S23. doi:10.5664/jcsm.26932
McGrane IR, Leung JG, St. Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19-26. doi:10.1016/j.sleep.2014.09.011
Mun JG, Wang D, Doerflein Fulk DL, et al. A randomized, double-blind, crossover study to investigate the pharmacokinetics of extended-release melatonin compared to immediate-release melatonin in healthy adults. J Diet Suppl. 2023;21:182-194. doi:10.1080/19390211.2023.2206475
Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18(7):598-603. doi:10.1093/sleep/18.7.598
Zhdanova IV, Tucci V. Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol. 2003;5:225-229. doi:10.1007/s11940-003-0013-0
Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev. 2005;9(1):51-65. doi:10.1016/j.smrv.2004.04.003
Besag FMC, Vasey MJ, Lao KSJ, Wong ICK. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs. 2019;33(12):1167-1186. doi:10.1007/s40263-019-00680-w
Tobeiha M, Jafari A, Fadaei S, et al. Evidence for the benefits of melatonin in cardiovascular disease. Front Cardiovasc Med. 2022;9(June):1-39. doi:10.3389/fcvm.2022.888319
Wang W, Gao J. Effects of melatonin on protecting against lung injury (Review. Exp Ther Med. 2021;21(3):228. doi:10.3892/etm.2021.9659
Mortezaee K, Khanlarkhani N. Melatonin application in targeting oxidative-induced liver injuries: a review. J Cell Physiol. 2018;233(5):4015-4032. doi:10.1002/jcp.26209
Lusardi P, Piazza E, Fogari R Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 2000;49(5):423-427. doi:10.1046/j.1365-2125.2000.00195.x